((3-chloro-phenyl)sulfanyl)-acetic acid methyl ester

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 英文名称: ((3-chloro-phenyl)sulfanyl)-acetic acid methyl ester
• 英文别名: (3-chloro-phenylsulfanyl)-acetic acid methyl ester；Methyl 2-(3-chlorophenyl)sulfanylacetate
• 化学式: C₉H₉ClO₂S
• 分子量: 216.688
• InChiKey: JUBPCINHJIFNTK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  51.6
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  ((3-chloro-phenyl)sulfanyl)-acetic acid methyl ester 在 双氧水 、 sodium hydroxide 作用下， 以 1,4-二氧六环 、 水 、 溶剂黄146 为溶剂， 反应 1.17h， 生成 (3-chloro-benzenesulfinyl)-acetic acid
  参考文献：
  名称：

  [EN] PARP INHIBITORS
  [FR] INHIBITEURS DE PARP

  摘要：

  本申请披露了式I的化合物，其中变量R1和R2如本文所述，这些化合物是PARP的抑制剂，并提供了含有式I化合物的化合物和组合物。本申请还提供了使用披露的PARP抑制剂治疗PARP介导的疾病和疾病的方法。

  公开号：

  WO2013030205A1
• 作为产物：
  描述：

  3-氯苯硫酚 、 溴乙酸甲酯 在 N-甲基吗啉 作用下， 以 四氢呋喃 为溶剂， 反应 20.0h， 生成 ((3-chloro-phenyl)sulfanyl)-acetic acid methyl ester
  参考文献：
  名称：

  [EN] PARP INHIBITORS
  [FR] INHIBITEURS DE PARP

  摘要：

  本申请披露了式I的化合物，其中变量R1和R2如本文所述，这些化合物是PARP的抑制剂，并提供了含有式I化合物的化合物和组合物。本申请还提供了使用披露的PARP抑制剂治疗PARP介导的疾病和疾病的方法。

  公开号：

  WO2013030205A1

文献信息

• Pyrolysis of (2-Phenylethyl)phenylsulfonium Ylides.
  作者：Toshiaki Yoshimura、Atsushi Motoyama、Akiko Morishige、Eiichi Tsukurimichi、Choichiro Shimasaki、Kiyoshi Hasegawa

  DOI：10.1246/bcsj.66.174

  日期：——

  In order to obtain information concerning the reaction mechanism of the pyrolysis of sulfonium ylides bearing a substituted phenyl group on the 2-position in the S-ethyl group of ethylphenylsulfonium ylide, (2-phenylethyl)phenylsulfonium bis(methoxycarbonyl)methylide (1) and dicyanomethylide (2) were subjected to pyrolysis in benzene. The reaction rates of 1 and 2 at 140 °C were 6.0- and 3.2-times faster than those of ethylphenylsulfonium bis(methoxycarbonyl)methylide and dicyanomethylide, respectively. The activation parameters for 1 were ΔH‡ = 125 kJ mol−1 and ΔS‡ = −3.8 J K−1 mol−1, while those for 2 were ΔH‡ = 124 kJ mol−1 and ΔS‡ = −2.5 J K−1 mol−1. Substituent effects on the β-phenyl groups in 1 and 2 afforded positive Hammett ρ-values: ρ = 0.49 (γ = 0.997) and ρ = 0.26 (γ = 0.993), respectively.From the obtained results, it was suggested that the pyrolysis proceeds through essentially a concerted intramolecular cis-elimination inclined toward a slightly carbanion-like type from an E1-like type by introducing a phenyl substituent at the 2-position of the ethyl group in the ethylphenylsulfonium ylide.

  为了获取有关乙基苯基亚磺酸乙酯中乙基的2-位上带有取代苯基的磺酸亚磺酸分解反应机理的信息，将（2-苯乙基）苯基亚磺酸双（甲氧基羰基）甲亚基（1）和双氰基甲亚基（2）在苯中进行分解。在140°C时，1和2的反应速率分别比乙基苯基亚磺酸双（甲氧基羰基）甲亚基和双氰基甲亚基快6.0倍和3.2倍。1的活化参数为ΔH‡ = 125 kJ mol−1，ΔS‡ = -3.8 J K−1 mol−1，而2的活化参数为ΔH‡ = 124 kJ mol−1，ΔS‡ = -2.5 J K−1 mol−1。1和2中β-苯基的取代效应提供了正的Hammett ρ值：ρ = 0.49（γ = 0.997）和ρ = 0.26（γ = 0.993）。从得到的结果可以看出，通过在乙基苯基亚磺酸乙的乙基的2-位引入苯基取代基，基本上是通过倾向于稍微类似于碳负离子的顺式消除过程，从而类似于E1型反应。
• [EN] TETRAHYDROCARBAZOLES AND DERIVATIVES<br/>[FR] TETRAHYDROCARBAZOLES ET DERIVES
  申请人：HOFFMANN LA ROCHE

  公开号：WO2005092856A1

  公开（公告）日：2005-10-06

  The present invention relates to compounds of the formula (I) wherein R1, R2, R3, R4, R5, X1, X2, X3, X4, n, and k are defined in the description and claims, and pharmaceutically acceptable salts and/or pharmaceutically acceptable esters thereof. The compounds are useful for in the treatment and prophylaxis of diseases which are modulated by LXRα and/or LXRß agonists, including increased lipid and cholesterol levels, particularly low HDL-cholesterol, high LDL-cholesterol, atherosclerotic diseases, diabetes, particularly non-insulin dependent diabetes mellitus, metabolic syndrome, dyslipidemia, Alzheimer's disease, sepsis, inflammatory diseases such as colitis, pancreatitis, cholestasis/fibrosis of the liver, and diseases that have an inflammatory component such as Alzheimer's disease or impaired/improvable cognitive function.

  本发明涉及式(I)的化合物，其中R1、R2、R3、R4、R5、X1、X2、X3、X4、n和k在描述和权利要求中有定义，并且其药学上可接受的盐和/或药学上可接受的酯。这些化合物对于治疗和预防由LXRα和/或LXRß激动剂调节的疾病是有用的，包括增加的脂质和胆固醇水平，特别是低HDL-胆固醇、高LDL-胆固醇、动脉粥样硬化疾病、糖尿病，特别是非胰岛素依赖型糖尿病，代谢综合征，血脂异常，阿尔茨海默病，败血症，炎症性疾病如结肠炎、胰腺炎、肝胆瘀积/肝纤维化，以及具有炎症成分的疾病，如阿尔茨海默病或认知功能受损/可改善的疾病。
• Tetrahydrocarbazoles and derivatives
  申请人：Dehmlow Henrietta

  公开号：US20050215577A1

  公开（公告）日：2005-09-29

  The present invention relates to compounds of the formula (I) wherein R 1 , R 2 , R 3 , R 4 , R 5 , X 1 , X 2 , X 3 , X 4 , n, and k are defined in the description and claims, and pharmaceutically acceptable salts and/or pharmaceutically acceptable esters thereof. The compounds are useful for in the treatment and prophylaxis of diseases which are modulated by LXRα and/or LXRβ agonists, including increased lipid and cholesterol levels, particularly low HDL-cholesterol, high LDL-cholesterol, atherosclerotic diseases, diabetes, particularly non-insulin dependent diabetes mellitus, metabolic syndrome, dyslipidemia, Alzheimer's disease, sepsis, inflammatory diseases such as colitis, pancreatitis, cholestasis/fibrosis of the liver, and diseases that have an inflammatory component such as Alzheimer's disease or impaired/improvable cognitive function.

  本发明涉及式(I)的化合物，其中R1、R2、R3、R4、R5、X1、X2、X3、X4、n和k在说明书和权利要求中有定义，并且其药学上可接受的盐和/或药学上可接受的酯。这些化合物在LXRα和/或LXRβ激动剂调节的疾病的治疗和预防中有用，包括增加的脂质和胆固醇水平，特别是低HDL-胆固醇，高LDL-胆固醇，动脉粥样硬化疾病，糖尿病，特别是非胰岛素依赖性糖尿病，代谢综合征，脂质代谢异常，阿尔茨海默病，败血症，炎症性疾病，如结肠炎，胰腺炎，肝胆瘤/纤维化和具有炎症成分的疾病，如阿尔茨海默病或受损/可改善的认知功能。
• TETRAHYDROCARBAZOLES AND DERIVATIVES
  申请人：Dehmlow Henrietta

  公开号：US20100216833A1

  公开（公告）日：2010-08-26

  The present invention relates to compounds of the formula (I) wherein R 1 , R 2 , R 3 , R 4 , R 5 , X 1 , X 2 , X 3 , X 4 , n, and k are defined in the description and claims, and pharmaceutically acceptable salts and/or pharmaceutically acceptable esters thereof. The compounds are useful for in the treatment and prophylaxis of diseases which are modulated by LXRα and/or LXRβ agonists, including increased lipid and cholesterol levels, particularly low HDL-cholesterol, high LDL-cholesterol, atherosclerotic diseases, diabetes, particularly non-insulin dependent diabetes mellitus, metabolic syndrome, dyslipidemia, Alzheimer's disease, sepsis, inflammatory diseases such as colitis, pancreatitis, cholestasis/fibrosis of the liver, and diseases that have an inflammatory component such as Alzheimer's disease or impaired/improvable cognitive function.

  本发明涉及式（I）的化合物，其中R1、R2、R3、R4、R5、X1、X2、X3、X4、n和k在说明书和权利要求书中定义，并且其药学上可接受的盐和/或药学上可接受的酯。该化合物用于治疗和预防LXRα和/或LXRβ激动剂调节的疾病，包括增加的脂质和胆固醇水平，特别是低HDL胆固醇，高LDL胆固醇，动脉粥样硬化疾病，糖尿病，特别是非胰岛素依赖性糖尿病，代谢综合征，血脂异常，阿尔茨海默病，败血症，炎症性疾病，如结肠炎，胰腺炎，肝胆瘤/纤维化以及有炎症成分的疾病，例如阿尔茨海默病或受损/可改善的认知功能。
• Indole derivative used as CRTH2 inhibitor
  申请人：CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.

  公开号：US10800765B2

  公开（公告）日：2020-10-13

  The present application discloses an indole as represented by formula (I) used as a CRTH2 inhibitor, and a pharmaceutically acceptable salt or tautomer of the indole, and an application of same in treating a disease related to a CRTH2 receptor.

  本申请公开了一种由式（I）表示的用作 CRTH2 抑制剂的吲哚、该吲哚的药学上可接受的盐或同系物，以及其在治疗与 CRTH2 受体有关的疾病中的应用。